Keyphrases
Patient-derived Xenograft
100%
Triple-negative Breast Cancer
76%
Breast Cancer
56%
Tumor
48%
Breast Cancer Patients
42%
Estrogen Receptor 1 (ESR1)
39%
Breast Cancer Xenograft
24%
Patient-derived Tumor Xenograft
23%
Endocrine Therapy
20%
Proteomics
18%
Xenograft
18%
Metastatic Breast Cancer
18%
Proteogenomics
16%
Tumor Growth
16%
Metastasis
16%
Patient-derived
15%
Response Predictors
13%
Mass Spectrometry
13%
ESR1 mutation
12%
Breast Tumor
12%
Basal-like
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Endocrine Resistance
11%
Response to Therapy
11%
Proteome
11%
Phosphorylation
10%
Targeted Therapy
10%
Cyclin-dependent Kinase 4 (CDK4)
10%
Targeted Treatment
10%
Endocrine-resistant Breast Cancer
10%
PI3K Inhibitor
10%
Chemotherapy Resistance
10%
Proteomic Analysis
10%
Therapy-resistant
10%
Radiomics
10%
Primary Breast Cancer
10%
Magnetic Resonance Imaging
10%
Palbociclib
9%
Estrogen Receptor
9%
Pathway Activity
9%
Mammalian Target of Rapamycin (mTOR)
9%
Poor Prognosis
9%
Eribulin
9%
Cancer Xenograft
9%
Engraftment
9%
Hormonal Stimulation
9%
Chemotherapy Response
9%
Copy number Profiling
9%
Comprehensive Characterization
9%
Radiomics Signature
9%
Biochemistry, Genetics and Molecular Biology
Proteomics
51%
Cancer Cell
32%
Genomics
32%
Estrogen Receptor
26%
Tumor Progression
20%
Proteome
20%
Kinase
20%
Phosphotransferase
20%
Proteogenomics
18%
Carcinogenesis
18%
DNA Sequence
16%
Transcriptomics
14%
Gene Expression
14%
Radiomics
13%
Ligand Binding Domain
12%
Quantitative Proteomics
11%
YAP1
11%
Protein Kinase B
10%
Mass Spectrometry
10%
RNA Sequence
9%
Drug Resistance
9%
Reprogramming
9%
Somatic Mutation
9%
Phosphoinositide 3-Kinase
9%
Gene Amplification
9%
Programmed Cell Death
9%
Cyclin-Dependent Kinase 4
9%
Cyclin-Dependent Kinase 6
9%
Growth Inhibition
9%
Clinical Trial
8%
Mesenchymal-Epithelial Transition
8%
Magnetic Resonance Imaging
8%
Epidermal Growth Factor Receptor
8%
Kinome
8%
Estrogen Receptor Alpha
8%
Phosphoprotein
8%
Gene Fusion
7%
Mouse Model
7%
C-Terminus
7%
Genetics
6%
Neratinib
6%
Preclinical Study
6%
Pan-cancer
6%
Tandem Mass Spectrometry
6%
Tumor Volume
6%
Antineoplastic Activity
6%
Protein Expression
6%
Cell Mutant
5%
Phosphoproteomics
5%
Drug Response
5%
Medicine and Dentistry
Breast Cancer
66%
Xenograft
62%
Triple Negative Breast Cancer
36%
Neoplasm
33%
Tumor Xenograft
28%
Hormone Therapy
25%
Metastatic Carcinoma
22%
Malignant Neoplasm
16%
Polyethylene Terephthalate
14%
Radiomics
13%
Tumor Progression
13%
Positron Emission Tomography
12%
Diseases
12%
CDK4/6 Inhibitor
11%
Therapy Resistance
10%
Neoadjuvant Chemotherapy
10%
Carcinogenesis
10%
Metastatic Breast Cancer
9%
Basal Like Breast Cancer
9%
Estrogen Receptor
8%
Primary Tumor
8%
In Vitro
8%
Zirconium 89
7%
Clinical Trial
7%
Palbociclib
6%
Biological Marker
6%
Estrogen Receptor Positive Breast Cancer
6%
Magnetic Resonance Imaging
6%
Cancer Research
6%
Phosphotransferase
6%
Epidermal Growth Factor Receptor
6%
Cancer
6%
Drug Resistance
5%
Tumor Imaging
5%
DNA Mismatch Repair
5%
Fluorodeoxyglucose F 18
5%
Cell Mutant
5%
Solid Malignant Neoplasm
5%
Cell Cycle Regulation
5%
Tyrosine-Kinase Inhibitor
5%
Protein Kinase B
5%
